O	0	6	Effect
O	7	9	of
B-intervention	10	21	intravenous
I-intervention	22	31	lidocaine
O	32	34	on
O	35	48	postoperative
O	49	57	recovery
O	58	60	of
O	61	69	patients
O	70	80	undergoing
O	81	91	mastectomy
O	91	92	:
O	93	94	a
O	95	101	double
O	101	102	-
O	102	107	blind
O	107	108	,
O	109	116	placebo
O	116	117	-
O	117	127	controlled
O	128	138	randomized
O	139	144	trial
O	144	145	.

O	146	149	One
O	150	152	of
O	153	156	the
O	157	167	modalities
O	168	170	of
O	171	180	treatment
O	181	184	for
O	185	191	breast
O	192	198	cancer
O	199	206	surgery
O	207	211	pain
O	212	214	is
O	215	222	opioids
O	222	223	,
O	224	227	and
O	228	235	opioids
O	236	239	are
O	240	250	associated
O	251	255	with
O	256	263	adverse
O	264	271	effects
O	272	276	such
O	277	279	as
O	280	287	itching
O	288	291	and
O	292	305	postoperative
O	306	312	nausea
O	313	316	and
O	317	325	vomiting
O	326	327	(
O	327	331	PONV
O	331	332	)
O	332	333	.

O	334	345	Intravenous
O	346	347	(
O	347	349	IV
O	349	350	)
O	351	360	lidocaine
O	361	364	has
O	365	369	been
O	370	375	shown
O	376	378	to
O	379	385	reduce
O	386	392	opioid
O	393	404	consumption
O	405	408	and
O	409	411	to
O	412	419	improve
O	420	427	overall
O	428	441	postoperative
O	442	450	outcomes
O	451	453	in
O	454	463	abdominal
O	464	471	surgery
O	471	472	.

O	473	475	In
O	476	480	this
O	481	486	study
O	486	487	,
O	488	490	we
O	491	497	tested
O	498	501	the
O	502	508	effect
O	509	511	of
O	512	526	intraoperative
O	527	529	IV
O	530	539	lidocaine
O	540	548	infusion
O	549	551	on
O	552	555	the
O	556	563	quality
O	564	566	of
O	567	580	postoperative
O	581	589	recovery
O	590	595	after
O	596	602	breast
O	603	609	cancer
O	610	617	surgery
O	617	618	.

B-total-participants	619	626	Seventy
I-total-participants	626	627	-
I-total-participants	627	630	one
B-eligibility	631	639	patients
I-eligibility	640	650	undergoing
I-eligibility	651	657	breast
I-eligibility	658	664	cancer
I-eligibility	665	672	surgery
O	673	677	were
O	678	686	randomly
O	687	695	assigned
O	696	698	to
O	699	706	receive
O	707	713	either
B-control	714	721	placebo
O	722	723	(
O	723	728	group
O	729	730	P
O	730	731	;
O	732	733	n
O	734	735	=
B-control-participants	736	738	34
O	738	739	)
O	740	742	or
O	743	745	IV
O	746	755	lidocaine
O	756	757	(
O	757	762	group
O	763	764	L
O	764	765	;
O	766	767	n
O	768	769	=
B-intervention-participants	770	772	37
O	772	773	,
O	774	779	bolus
O	780	781	1
O	781	782	.
O	782	783	5
O	784	786	mg
O	786	787	/
O	787	789	kg
O	790	792	at
O	793	802	induction
O	802	803	,
O	804	808	then
O	809	817	infusion
O	818	820	at
O	821	822	2
O	823	825	mg
O	825	826	/
O	826	828	kg
O	828	829	/
O	829	830	h
O	830	831	,
O	832	839	stopped
O	840	841	2
O	842	847	hours
O	848	853	after
O	854	857	the
O	858	861	end
O	862	864	of
O	865	872	surgery
O	872	873	)
O	874	876	in
O	877	878	a
O	879	890	prospective
O	891	897	double
O	897	898	-
O	898	903	blind
O	904	910	design
O	910	911	.

O	912	926	Intraoperative
O	927	930	and
O	931	944	postoperative
O	945	953	morphine
O	954	965	consumption
O	966	969	was
O	970	980	calculated
O	980	981	.

O	982	995	Postoperative
O	996	1000	pain
O	1001	1007	scores
O	1007	1008	,
O	1009	1013	PONV
O	1013	1014	,
O	1015	1018	and
O	1019	1026	fatigue
O	1027	1031	were
O	1032	1040	assessed
O	1041	1043	at
O	1044	1045	2
O	1045	1046	,
O	1047	1049	24
O	1049	1050	,
O	1051	1054	and
O	1055	1057	48
O	1058	1063	hours
O	1064	1069	after
O	1070	1077	surgery
O	1077	1078	.

O	1079	1087	Duration
O	1088	1090	of
O	1091	1104	postoperative
O	1105	1113	hospital
O	1114	1118	stay
O	1119	1122	was
O	1123	1131	recorded
O	1131	1132	.

O	1133	1145	Demographics
O	1146	1150	were
O	1151	1154	the
O	1155	1159	same
O	1160	1167	between
O	1168	1171	the
O	1172	1178	groups
O	1178	1179	.

O	1180	1185	There
O	1186	1189	was
O	1190	1192	no
O	1193	1206	statistically
O	1207	1218	significant
O	1219	1229	difference
O	1230	1232	in
B-outcome	1233	1247	intraoperative
I-outcome	1248	1250	or
I-outcome	1251	1264	postoperative
I-outcome	1265	1273	morphine
I-outcome	1274	1285	consumption
O	1286	1287	(
O	1287	1288	P
O	1289	1290	=
O	1291	1292	0
O	1292	1293	.
O	1293	1296	188
O	1297	1300	and
O	1301	1302	P
O	1303	1304	=
O	1305	1306	0
O	1306	1307	.
O	1307	1310	758
O	1310	1311	)
O	1312	1319	between
O	1320	1326	groups
O	1326	1327	.

B-outcome	1328	1335	Overall
I-outcome	1336	1340	pain
I-outcome	1341	1347	scores
I-outcome	1348	1354	either
I-outcome	1355	1357	at
I-outcome	1358	1362	rest
I-outcome	1363	1365	or
I-outcome	1366	1374	activity
O	1375	1376	(
O	1376	1377	P
O	1378	1379	=
O	1380	1381	0
O	1381	1382	.
O	1382	1385	348
O	1386	1389	and
O	1390	1391	P
O	1392	1393	=
O	1394	1395	0
O	1395	1396	.
O	1396	1399	810
O	1399	1400	,
O	1401	1413	respectively
O	1413	1414	)
O	1414	1415	,
B-outcome	1416	1420	PONV
O	1421	1422	(
O	1422	1423	P
O	1424	1425	=
O	1426	1427	0
O	1427	1428	.
O	1428	1431	350
O	1431	1432	)
O	1432	1433	,
B-outcome	1434	1441	fatigue
O	1442	1443	(
O	1443	1444	P
O	1445	1446	=
O	1447	1448	0
O	1448	1449	.
O	1449	1452	758
O	1452	1453	)
O	1453	1454	,
O	1455	1457	or
B-outcome	1458	1466	duration
I-outcome	1467	1469	of
I-outcome	1470	1483	postoperative
I-outcome	1484	1492	hospital
I-outcome	1493	1497	stay
O	1498	1499	(
O	1499	1500	P
O	1501	1502	=
O	1503	1504	0
O	1504	1505	.
O	1505	1508	218
O	1508	1509	)
O	1510	1514	were
O	1515	1518	not
O	1519	1532	statistically
O	1533	1542	different
O	1542	1543	.

O	1544	1547	Our
O	1548	1556	findings
O	1557	1560	did
O	1561	1564	not
O	1565	1569	show
O	1570	1571	a
O	1572	1583	significant
O	1584	1590	effect
O	1591	1593	of
O	1594	1596	IV
O	1597	1606	lidocaine
O	1607	1613	during
O	1614	1620	breast
O	1621	1627	cancer
O	1628	1635	surgery
O	1636	1638	on
O	1639	1645	opioid
O	1646	1657	consumption
O	1657	1658	,
O	1659	1663	pain
O	1664	1669	score
O	1669	1670	,
O	1671	1675	PONV
O	1675	1676	,
O	1677	1679	or
O	1680	1687	fatigue
O	1687	1688	,
O	1689	1699	indicating
O	1700	1704	that
O	1705	1708	the
O	1709	1716	benefit
O	1717	1719	of
O	1720	1724	this
O	1725	1733	approach
O	1734	1738	does
O	1739	1742	not
O	1743	1753	generalize
O	1754	1760	across
O	1761	1764	all
O	1765	1770	types
O	1771	1773	of
O	1774	1781	surgery
O	1781	1782	.
